Hikma improves performance in FTSE4Good Index

Hikma is pleased to announce that its performance in the FTSE4Good Index has improved with a score of 3.5, compared with 3.0 a year ago. This puts Hikma at the 78th percentile in terms of sustainability performance as compared to other listed healthcare companies, up from the 57th percentile last year. The FTSE4Good Index measures the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices and Hikma has been included in the index since 2014.

Press Release Corporate 5 August 2020

The most notable score increases for Hikma were for Environment, attributable to the improvement in management of climate change issues.  In the last year, Hikma has successfully completed a number of projects including the completion of a steam trap monitoring system in Columbus, the installation of PV/net metering solar panels at facilities in Jordan and Portugal, the installation of charging stations for electric vehicles at company facilities, the usage of greener fuel options and the switch to hybrid-powered vehicles.

Hana Darwazah, VP of CSR for Hikma said, “We are proud of the work we’ve accomplished over the past year. Our improved score is a testament to the hard work of our team and the measures we’ve taken. ESG is an area we continue to focus on, and we look forward to continuing our progress and continuing to use our business to promote positive change.”

For more information on Hikma’s sustainability efforts, visit the website, or read about one of our sustainability case studies.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.